Evaluating the Diagnostic Accuracy of Point-of-Care CXCL13 Measurements for Lyme Neuroborreliosis
Diagnostics · 07.05.2026 · 16 (10) · 1424
DOI: 10.3390/diagnostics16101424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 07.05.2026. Verfasst von Lasse Fjordside und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rigshospitalet.
Abstract (Originalsprache)
Background
Measurements of the B-cell attracting chemokine CXCL13 in cerebrospinal fluid (CSF) has become increasingly popular in the diagnostic work-up for Lyme neuroborreliosis (LNB). ReaScan is a point-of-care test for CXCL13 with a short turnaround-time. However, the diagnostic cut-off value for LNB has not been firmly established.
Methods
We conducted a retrospective cohort study including all ReaScan CXCL13 measurements performed on CSF samples at Copenhagen University Hospital, Rigshospitalet, from patients of all ages suspected for LNB in 2020–2025. Patients were categorized in accordance with the European Federation of Neurological Societies (EFNS) diagnostic guidelines for LNB as definite, possible, or non-LNB based on a retrospective review of patient records. The manufacturer-informed cut-off value for positive test results was applied and the diagnostic accuracy was calculated based on the ability to identify patients with possible and definite LNB. In addition, a Youden-index optimized cut-off value was calculated and evaluated on the cohort.
Results
A total of 1181 ReaScan CXCL13 measurements from children and adults were evaluated against final diagnoses. Using the manufacturer-informed cut-off value (14 AU/mL) ReaScan CXCL13 reached a sensitivity of 38% and a specificity of 98% for identifying cases of possible and definite LNB. A Youden-index optimized cut-off value (1.79 AU/mL) significantly improved the diagnostic accuracy reaching a sensitivity value of 71% and a specificity of 92%.
Conclusions
These real-world clinical data suggest that the current cut-off value for the ReaScan CXCL13 analysis is not optimal for diagnosing LNB. Lowering the cut-off level would significantly increase the diagnostic accuracy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
- Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
ORCID-Profile: Lasse Fjordside, Mathilde Ørbæk, Thomas Bryrup, Alex Christian Yde Nielsen, Helene Mens, Anne-Mette Lebech
Förderung
- Rigshospitalet
Zitieren
APA
Fjordside, L., Ørbæk, M., Bryrup, T., Kaas, L. H., Nielsen, A. C. Y., Kirkby, N. S., Mens, H., & Lebech, A. M. (2026). Evaluating the Diagnostic Accuracy of Point-of-Care CXCL13 Measurements for Lyme Neuroborreliosis. Diagnostics, 16(10), 1424. https://doi.org/10.3390/diagnostics16101424
Vancouver
Fjordside L, Ørbæk M, Bryrup T, Kaas LH, Nielsen ACY, Kirkby NS, et al. Evaluating the Diagnostic Accuracy of Point-of-Care CXCL13 Measurements for Lyme Neuroborreliosis. Diagnostics. 2026;16(10):1424. doi:10.3390/diagnostics16101424
BibTeX
@article{Fjordside2026,
author = {Fjordside, Lasse and Ørbæk, Mathilde and Bryrup, Thomas and Kaas, Louise Helvig and Nielsen, Alex Christian Yde and Kirkby, Nikolai Søren and Mens, Helene and Lebech, Anne-Mette},
title = {Evaluating the Diagnostic Accuracy of Point-of-Care CXCL13 Measurements for Lyme Neuroborreliosis},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {10},
pages = {1424},
doi = {10.3390/diagnostics16101424}
}
EUVIMED